Your browser doesn't support javascript.
More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.
Lopez-Leon, Sandra; Wegman-Ostrosky, Talia; Perelman, Carol; Sepulveda, Rosalinda; Rebolledo, Paulina A; Cuapio, Angelica; Villapol, Sonia.
  • Lopez-Leon S; Drug Development, Novartis Pharmaceuticals, Florham Park, NJ, USA.
  • Wegman-Ostrosky T; Instituto Nacional de Cancerología, Subdirección de Investigación Básica, Mexico City, Mexico.
  • Perelman C; National Autonomous University of Mexico, SOMEDICyT, RedMPC, Mexico City, Mexico.
  • Sepulveda R; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Rebolledo PA; Divison of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
  • Cuapio A; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  • Villapol S; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Sci Rep ; 11(1): 16144, 2021 08 09.
Article in English | MEDLINE | ID: covidwho-1349688
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
COVID-19 can involve persistence, sequelae, and other medical complications that last weeks to months after initial recovery. This systematic review and meta-analysis aims to identify studies assessing the long-term effects of COVID-19. LitCOVID and Embase were searched to identify articles with original data published before the 1st of January 2021, with a minimum of 100 patients. For effects reported in two or more studies, meta-analyses using a random-effects model were performed using the MetaXL software to estimate the pooled prevalence with 95% CI. PRISMA guidelines were followed. A total of 18,251 publications were identified, of which 15 met the inclusion criteria. The prevalence of 55 long-term effects was estimated, 21 meta-analyses were performed, and 47,910 patients were included (age 17-87 years). The included studies defined long-COVID as ranging from 14 to 110 days post-viral infection. It was estimated that 80% of the infected patients with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%). Multi-disciplinary teams are crucial to developing preventive measures, rehabilitation techniques, and clinical management strategies with whole-patient perspectives designed to address long COVID-19 care.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Attention Deficit Disorder with Hyperactivity / Dyspnea / Alopecia / Fatigue / COVID-19 / Headache Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Long Covid Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-95565-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Attention Deficit Disorder with Hyperactivity / Dyspnea / Alopecia / Fatigue / COVID-19 / Headache Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Long Covid Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-95565-8